XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
XTL Biopharmaceuticals Ltd., a company known for its intellectual property in lupus treatment, has encountered a financial dispute following its acquisition of The Social Proxy Ltd., an AI web data company. The controversy involves financial representations made by The Social Proxy’s CEO and former shareholders, prompting XTL to form a review committee to resolve the issue. Despite the ongoing review, XTL continues to focus on expanding its portfolio and exploring strategic partnerships.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.
